Advances in Multiple Sclerosis Research-Series I
Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Is...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (334 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 05233nam-a2201669z--4500 | ||
|---|---|---|---|
| 001 | 993545117504498 | ||
| 005 | 20231214132850.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000042045 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68583 | ||
| 035 | |a (EXLCZ)995400000000042045 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Matsoukas, John |4 edt | |
| 245 | 1 | 0 | |a Advances in Multiple Sclerosis Research-Series I |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (334 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | |a Open access |f Unrestricted online access |2 star | ||
| 520 | |a Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular multiple sclerosis, for over 20 years. Delivery methods that are used to modulate effective and long-lasting immune responses have been the major focus. This Special Issue focused on delivery methods to be used for vaccines, immunotherapeutic approaches, drug design, and anti-inflammatories and their outcomes in preclinical studies and clinical trials. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a multiple sclerosis | ||
| 653 | |a inflammation | ||
| 653 | |a oxidative | ||
| 653 | |a biomarker | ||
| 653 | |a sample size | ||
| 653 | |a autoimmune encephalitis | ||
| 653 | |a plasma exchange | ||
| 653 | |a autoimmunity | ||
| 653 | |a immunotherapeutics | ||
| 653 | |a clinical outcomes | ||
| 653 | |a major depression | ||
| 653 | |a bupropion | ||
| 653 | |a S-adenosylmethionine | ||
| 653 | |a vitamin D3 | ||
| 653 | |a yoga | ||
| 653 | |a craniopharyngioma | ||
| 653 | |a fractionated stereotactic radiation treatments | ||
| 653 | |a sphenoid sinusitis | ||
| 653 | |a cranial nerve-VI palsy | ||
| 653 | |a autoimmune diseases | ||
| 653 | |a immune thrombocytopenic purpura | ||
| 653 | |a alemtuzumab | ||
| 653 | |a antibodies against GluR3 peptide | ||
| 653 | |a cognitive impairment | ||
| 653 | |a diagnosis | ||
| 653 | |a neuropsychological assessment | ||
| 653 | |a short intracortical inhibition | ||
| 653 | |a intracortical facilitation | ||
| 653 | |a fampridine | ||
| 653 | |a walking disability | ||
| 653 | |a TSPAN32 | ||
| 653 | |a tetraspanins | ||
| 653 | |a cellular immunity | ||
| 653 | |a memory T cells | ||
| 653 | |a tDCS | ||
| 653 | |a neuroimaging | ||
| 653 | |a positron emission tomography | ||
| 653 | |a cerebral blood flow | ||
| 653 | |a probiotics | ||
| 653 | |a Streptococcus thermophilus | ||
| 653 | |a ST285 | ||
| 653 | |a MBP83–99 peptide | ||
| 653 | |a mannan | ||
| 653 | |a immune modulation | ||
| 653 | |a agonist peptide | ||
| 653 | |a gut microbiome | ||
| 653 | |a gut–brain axis | ||
| 653 | |a metagenomics | ||
| 653 | |a disease-modifying treatments | ||
| 653 | |a MS | ||
| 653 | |a vaccine | ||
| 653 | |a immunomodulation | ||
| 653 | |a carriers | ||
| 653 | |a B cell receptor | ||
| 653 | |a delivery methods | ||
| 653 | |a immunotherapy | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a T cell receptor | ||
| 653 | |a tolerance | ||
| 653 | |a diagnostic markers | ||
| 653 | |a immunoglobulins | ||
| 653 | |a kappa | ||
| 653 | |a free light chains | ||
| 653 | |a antigen-specific immunotherapies | ||
| 653 | |a tolerogenic vaccines | ||
| 653 | |a tolerance induction | ||
| 653 | |a central nervous system | ||
| 653 | |a myelin peptides | ||
| 653 | |a myelin basic protei | ||
| 653 | |a proteolipid protein | ||
| 653 | |a myelin oligodendrocyte glycoprotein | ||
| 653 | |a nanotechnology | ||
| 653 | |a drug delivery nanosystems | ||
| 653 | |a lipids | ||
| 653 | |a polymers | ||
| 653 | |a vaccines | ||
| 653 | |a nanoparticles | ||
| 653 | |a antigen-specific immunotherapy | ||
| 653 | |a experimental autoimmune encephalomyelitis | ||
| 653 | |a neurodegeneration | ||
| 653 | |a chloroquine | ||
| 653 | |a EAE | ||
| 653 | |a dendritic cells | ||
| 653 | |a microglia | ||
| 653 | |a astrocytes | ||
| 653 | |a oligodendrocytes | ||
| 653 | |a conformational analysis | ||
| 653 | |a peptides | ||
| 653 | |a altered peptide ligands | ||
| 653 | |a NMR spectroscopy | ||
| 653 | |a NOE-constraints | ||
| 653 | |a molecular dynamic | ||
| 653 | |a trimolecular complex | ||
| 653 | |a Multiple Sclerosis | ||
| 653 | |a early-onset | ||
| 653 | |a adult-onset | ||
| 653 | |a Human Leucocyte Antigens | ||
| 653 | |a immunogenetics | ||
| 653 | |a clinical phenotype | ||
| 653 | |a clinical outcome | ||
| 653 | |a therapeutics | ||
| 653 | |a antibody detection | ||
| 653 | |a ELISA | ||
| 653 | |a multivalency | ||
| 653 | |a N-glucosylated peptide epitopes | ||
| 653 | |a peptide | ||
| 653 | |a conjugation | ||
| 653 | |a MOG35-55 | ||
| 653 | |a Graphite/SiO2 electrode | ||
| 653 | |a voltammetry | ||
| 653 | |a HPLC | ||
| 653 | |a MS drugs | ||
| 776 | |z 3-03943-947-2 | ||
| 776 | |z 3-03943-948-0 | ||
| 700 | 1 | |a Apostolopoulos, Vasso |4 edt | |
| 700 | 1 | |a Matsoukas, John |4 oth | |
| 700 | 1 | |a Apostolopoulos, Vasso |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:34:47 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337907770004498&Force_direct=true |Z 5337907770004498 |b Available |8 5337907770004498 | ||